References
1. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive
myeloma. Blood. 1992;79(5):1130-1136.
2. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow
transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 1994;12(4):759-763.
3. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with
Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311-1320.
4. Gay F, Cerrato C, Petrucci MT, et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or
without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.
Journal of Clinical Oncology. 2019;37(15_suppl):8002-8002.
5. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus
bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation
therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre,
randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456-e468.
6. Hari P, Pasquini MC, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of
postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple
myeloma (MM). Journal of Clinical Oncology. 2020;38(15_suppl):8506-8506.
7. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and
dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood.
2020;136(8):936-945.